NEW YORK, June 15, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced that the U.S. Food and Drug Administration (“FDA”) has advised that it does not anticipate requiring further nonclinical toxicology studies in support of an ST-246(r) NDA filing.
